Earnings ·
Akari Therapeutics raises $8.6M in private placement and warrant exercises as R&D costs rise to $2.1M
AKTXAkari Therapeutics Plc
Akari Therapeutics reported second quarter 2026 financial results and highlighted operational progress. The company raised approximately $8.6 million in gross proceeds through a private placement of $5.5 million and warrant exercises worth $3.1 million, resulting in net proceeds of approximately $8.0 million. Research and development expenses increased to $2.1 million from $0.7 million in the prior year period, while general and administrative expenses remained stable at $2.5 million. The company reported a net loss of $4.8 million compared to $1.9 million previously. Cash reserves stood at $7.7 million as of June 30, 2026. Akari Therapeutics is an oncology biotechnology company developing antibody drug conjugates with a novel RNA splicing-targeting payload.